1. Trang chủ
  2. » Khoa Học Tự Nhiên

Prakash et al. Organic and Medicinal Chemistry Letters 2011, 1:5 docx

6 428 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 6
Dung lượng 276,64 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

In view of wide range of biological properties associated with 1,4-DHP and owing to the biological importance of the oxidation step of 1,4-DHP, we carried out the synthesis and antimicro

Trang 1

O R I G I N A L Open Access

Synthesis and antimicrobial evaluation of new

1,dihydro-pyrazolylpyridines and

4-pyrazolylpyridines

Om Prakash1, Khalid Hussain2, Ravi Kumar3*, Deepak Wadhwa4, Chetan Sharma5and Kamal R Aneja5

Abstract

Background: Dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylates (1,4-DHP) have now been recognized as vital drugs Some of these derivatives such as amlodipine, felodipine, isradipine, etc have been commercialized In view of wide range of biological properties associated with 1,4-DHP and owing to the biological importance of the oxidation step of 1,4-DHP, we carried out the synthesis and antimicrobial evaluation of new diethyl 1,4-dihydro-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g)

Results: Synthesis of a series of new diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) has been accomplished by multicomponent cyclocondensation reaction of ethyl

acetoacetate, 3-aryl-1-phenyl pyrazole-4-carboxaldehyde (1a-g) and ammonium acetate The dihydropyridines 2a-g were smoothly converted to new diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g) using HTIB ([Hydroxy (tosyloxy)iodo]benzene, Koser’s reagent) as the oxidizing agent The antimicrobial studies

of the title compounds, 2a-g &3a-g, are also described

Keywords: 1,4-Dihydro-4-pyrazolylpyridines, 4-pyrazolylpyridines, HTIB, oxidation, antibacterial activity, antifungal activity

Background

Dialkyl

1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxy-lates (1,4-DHP; Figure 1) have now been recognized as

vital drugs Some of these derivatives, such as amlodipine,

felodipine, isradipine, etc have been commercialized, and

it has been proven that their therapeutic success is

related to their efficacy to bind to calcium channels and

consequently to decrease the passage of the

transmem-brane calcium current [1-3] Further, cerebrocrast, a

dihydropyridine derivative, has been introduced as a

neu-roprotective agent [4] Together with calcium channel

blocker and neuroprotective activity, a number of

dihy-dropyridine derivatives have been found as vasodilators,

antihypertensive, bronchodilators, antiatherosclerotic,

hepatoprotective, antitumour, antimutagenic,

geroprotec-tive, antidiabetic and antiplatelet aggregation agents

[5-9] In a recent article, 4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-dihydropyridines have been shown to possess significant antimicrobial activity [10]

In addition to above, aromatization of 1,4-DHP has also attracted considerable attention in recent years as Böcker has demonstrated that metabolism of the above drugs involves a cytochrome P-450 catalysed oxidation

in the liver [11]

In view of wide range of biological properties asso-ciated with 1,4-DHP and the biological importance of the oxidation step of 1,4-DHP, we carried out the synthesis and antimicrobial evaluation of new diethyl 1,4-dihydro- 1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g)

Results and discussion

Chemistry

The synthetic scheme used for the synthesis of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)

* Correspondence: ravi.dhamija@rediffmail.com

3 Department of Chemistry, Dyal Singh College, Karnal 132 001, India

Full list of author information is available at the end of the article

© 2011 Prakash et al; licensee Springer This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,

Trang 2

pyridine-3,5-dicarboxylates (2a-g) is outlined in Scheme

1 Synthesis of the title compounds 2a-g was

accom-plished by multicomponent cyclocondensation reaction

of ethyl acetoacetate,

3-aryl-1-phenyl-pyrazole-carboxal-dehyde (1a-g) and ammonium acetate in ethanol The

purity of the compounds was checked by TLC and

ele-mental analysis Spectral data (IR,1H NMR (see

addi-tional files 1, 2, 3, 4 and 5, mass) of the newly

synthesized compounds 2a-g were in full agreement

with their proposed structures The IR spectra of

com-pounds 2a-g exhibited characteristic peak at

approxi-mately 1697 cm-1 because of the presence of ester group

(-COOEt), and peak due to -N-H stretch appeared in

the region 3300-3317 cm-1 In1H NMR of compounds

2a-g, the protons of C4-H and -NH of the

dihydropyri-dine ring resonate betweenδ 5 and 6 ppm

Hypervalent iodine (III) and iodine (V) reagents have

been used as green-oxidants for a variety of substrates

[12-17] Amongst the various reagents used, HTIB has

been reported to serve as a mild, fast and efficient

oxi-dant for the aromatization of Hantzsch

1,4-dihydropyri-dines to pyri1,4-dihydropyri-dines [18]

Thus, diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g) were further oxidized by treating with HTIB (Koser’s reagent) in dichloromethane (CH2Cl2) at room tempera-ture to afford new diethyl 2,6-dimethyl-4-(3-aryl-1-phe-nyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (3a-g) in good-to-excellent yields (Scheme 1) All the compounds 3a-g were unambiguously characterized on the basis of their spectral (IR,1H NMR (see additional files 6, 7, 8,

9, 10, 11 and 12) and mass) and elemental data

A plausible mechanism for the oxidation of dihydro-pyridines 2 to 3 is outlined in Scheme 2 The probable mechanism might involve the attack by N-H on PhI (OH)OTs, leading to the formation of intermediate 4 The intermediate 4 finally loses a molecule of iodoben-zene (PhI) to give 3

Pharmacology

All the synthesized compounds, 2a-g and 3a-g, were evaluated in vitro for their antibacterial activity against two gram-positive bacterial strains, Staphylococcus aur-eus &Bacillus subtilis and two gram-negative bacteria, namely, Escherichia coli and Pseudomonas aeruginosa and their activities were compared with a well-known commercial antibiotic, ciprofloxacin In addition, the synthesized compounds were also evaluated for their antifungal activity against Aspergillus niger &Aspergillus flavus and their antifungal potential was compared to reference drug, fluconazole Compounds possessed vari-able antibacterial activities against Gram-positive bac-teria, S aureus, B subtilis However, the compounds in this series were not effective against any Gram-negative bacteria, neither against E coli nor against P aeruginosa Results of antibacterial evaluation are summarized in Table 1

Compounds 2a-g and 3a-g showed zones of inhibition ranging between 14 and 20 mm On the basis of the zones of inhibition produced against the test bacteria, compounds 2b and 3a were found to be most effective against S aureus, showing the maximum zones of inhi-bition at 18 and 20 mm, respectively, and compounds 3a, 3e and 3g were found to be most effective against B

Figure 1 1,4-DHP.

Scheme 1 Synthesis of 1,4-DHP (2) and aromatization of 2 to 3

using HTIB. Scheme 2 Proposed mechanism for the oxidation of 2 to 3.

Trang 3

subtilis The remaining compounds showed fair activity

against gram-positive bacterial strains (Table 1) In the

whole series, the MIC (minimum inhibitoty

concentra-tion) values of various tested chemical compounds

ran-ged between 64 and 256μg/mL against gram-positive

bacteria Compounds 2b and 3a displayed good

antibac-terial activity with the lowest MIC value, 64 μg/ml

against S aureus Three compounds, 3a, 3e and 3g

pos-sessed antibacterial activity with MIC value of 64μg/mL

against B subtilis (Table 2)

Amongst the synthesized compounds, six compounds

2a, 2d, 2g, 3a, 3c and 3d showed more than 50%

myce-lial growth inhibition against A niger whereas

com-pounds, 2a, 2e, 2f, 3a, 3d and 3f were found to be

active against A flavus (Table 3)

From the overall result it is evident that compound 3a

could be identified as the most biologically active

member within this study with good antifungal and anti-bacterial profile

Conclusions

A series of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyri-dine-3,5-dicarboxylates (3a-g) has been synthesized with the hope of discovering new structure leads Compounds 2band 3a were found to be most effective against S aur-eusshowing the maximum zones of inhibition of 18 and

20 mm, respectively, and compounds 3a, 3e and 3g were found to be most effective against B subtilis Moreover, six compounds 2a, 2d, 2g, 3a, 3c and 3d showed more than 50% mycelial growth inhibition against A niger whereas compounds, 2a, 2e, 2f, 3a, 3d and 3f were found

to be active against A flavus; however, no compound was found superior over the reference drug

Finally, compound 3a could be identified as the most biologically active member within this study with an interesting antibacterial and antifungal profile

Experimental

Chemical synthesis

Melting points were taken in open capillaries and are uncorrected IR spectra were recorded on Perkin-Elmer

IR spectrophotometer The 1H NMR spectra were recorded on Brucker 300 MHz instrument The chemi-cal shifts are expressed in ppm units downfield from an internal TMS standard 3-Aryl-1-phenylpyrazole-4-car-boxaldehydes (1a-h), needed for the present study, were synthesized by Vilsmeier-Haack reaction according to the literature procedure [19]

Synthesis of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)

General procedure: A mixture of appropriate 3-aryl-1-phenylpyrazole-4-carboxaldehyde (1, 10 mmol), ethyl acetoacetate (20 mmol) and ammonium acetate (22 mmol) in ethanol was allowed to reflux on water bath for 25-30 min After completion of the reaction, the

Table 1 Antibacterial activity of chemical compounds

through agar well diffusion method

Compound Diameter of growth of inhibition zone (mm)a

S aureus Bacillus Subtilis E coli P aeruginosa

-Ciprofloxacin 27.6 26.3 25.0 25.3

-, No activity

a

Values, including diameter of the well (8 mm), are means of three replicates

Table 2 MIC (inμg/mL) of compounds obtained using

macrodilution method

Compound S.

aureus

Bacillus Subtilis

Compound S.

aureus

Bacillus Subtilis

Ciprofloxacin 5 5

Table 3 Antifungal activity of chemical compounds through poisoned food method (mycelial growth inhibition) (%)

Compound A niger A flavus Compound A niger A flavus

Fluconazole 81.1 77.7

Trang 4

reaction mixture was cooled to room temperature to

give pure diethyl

1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)

Characterization data of diethyl

1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)

2a: M.p.: 124°C; yield: 74%; IR (νmax, cm-1, KBr): 3323

(NH stretch), 1690 (-COOEt), 1207;1H NMR (CDCl3,δ,

ppm): 1.069-1.115 (t, 6H), 2.237 (s, 6H), 3.744-4.068 (m,

4 H), 5.318 (s, 1 H), 5.544 (s, 1 H), 7.221-7.424 (m, 4

H), 7.806 (s, 1 H), 7.681-7.868 (m, 6 H); mass: m/z

472.30 (M++ 1, 100%)

Anal Calcd for C28H29N3O4: C 71.33, H 6.15, N 8.91;

found: C 71.34, H 6.18, N 8.94; C 71.33, H 6.15, N 8.91

2b: M.p.: 189°C; yield: 70%; IR (νmax, cm-1, KBr): 3325

(NH stretch), 1697 (-OOEt), 1643, 1211; 1HNMR

(CDCl3, δ, ppm): 1.032-1.087 (t, 6 H), 2.225 (s, 6 H),

2.401 (s, 3 H), 3.730-4.095 (m, 4 H), 5.306 (s, 1 H),

5.722 (bs, 1 H), 7.205-7.282 (m, 3 H), 7.381-7.450 (m, 2

H), 7.664-7.692 (m, 2 H), 7.733 (s, 1 H), 7.742-7.769 (d,

2 H, J = 8.1 Hz); mass: m/z 486.20 (M++ 1, 100%)

Anal Calcd for C29H31N3O4: C 71.75, H 6.39, N 8.66;

found: C 71.71, H 6.42, N 8.66

2c: M.p.: 139°C; yield: 78%; IR (νmax, cm-1, KBr): 3317

(NH stretch), 1697 (-COOEt), 1643, 1211; 1H NMR

(CDCl3, δ, ppm): 1.079-1.127 (t, 6 H), 2.250 (s, 6 H),

3.866 (s, 3 H), 3.801-4.102 (m, 4 H), 5.288 (s, 1 H),

5.561 (s, 1 H), 6.962-6.991 (d, 2 H, J = 8.7 Hz),

7.209-7.440 (m, 3 H), 7.670-7.697 (d, 2 H, J = 8.7 Hz) 7.742 (s,

1 H), 7.785-7.814 (d, 2 H, J = 8.7 Hz); mass: m/z 502.32

(M+ + 1, 100%)

Anal Calcd for C29H31N3O5: C 69.46, H 6.19, N 8.38;

found: C 69.42, H 6.24, N 8.37

2d: M.p.: 175°C; yield: 72%; IR (νmax, cm-1, KBr): 3333

(NH stretch), 1697 (-COOEt), 1643, 1211; 1H NMR

(CDCl3, δ, ppm): 0.940-0.975 (t, 6 H), 2.521 (s, 6 H),

4.102-4.132 (m, 4 H), 5.175 (s, 1 H), 5.562 (s, 1 H),

6.962-6.991 (d, 2 H, J = 8.7 Hz), 7.281-7.513 (m, 5 H),

7.734 (d, 2 H, J = 7.5 Hz), 7.922 (s, 1 H); mass: m/z

490.26 (M++ 1, 100%)

Anal Calcd for C28H28N3O4F: C 68.71, H 5.73, N

8.58; found: C 68.72, H 5.75, N 8.56

2e: M.p.: 185°C; Yield: 76%; IR (νmax, cm-1, KBr): 3317

(NH stretch), 1697 (-COOEt), 1636, 1211; 1H NMR

(CDCl3, δ, ppm): 1.072-1.119 (t, 6 H), 2.280 (s, 6 H),

3.790-4.080 (m, 4 H), 5.285 (s, 1 H), 5.551 (s, 1 H),

7.235-7.454 (m, 5 H), 7.668-7.694 (d, 2 H) 7.814 (s, 1

H), 7.863-7.891 (d, 2 H, J = 8.4 Hz); mass: m/z 506.26,

508.24

Anal Calcd for C28H28N3O4Cl: C 66.47, H 5.54, N

8.31; found: C 66.47, H 5.55, N 8.31

2f: M.p.: 174°C; yield: 72%; IR (νmax, cm-1, KBr): 3564

(NH stretch), 1728 (-COOEt), 1242;1H NMR (CDCl3,δ,

ppm): 1.072-1.119 (t, 6 H), 2.275 (s, 6 H), 3.764-4.104

(m, 4 H), 5.284 (s, 1 H), 5.581 (s, 1 H), 7.234-7.452 (m,

3 H), 7.561-7.588 (d, 2 H, J = 7.8 Hz), 7.665-7.691 (d, 2

H, J = 7.8 Hz) 7.753 (s, 1 H), 7.806-7.834 (d, 2 H, J = 8.4 Hz); mass: m/z 550.31, 552.31

Anal Calcd for C28H28N3O4Br: C 61.20, H 5.10, N 7.65; found: C 61.09, H 5.14, N 7.64

2g: M.p.: 198°C; yield: 70%; IR (νmax, cm-1, KBr): 3302 (NH stretch), 1697 (-COOEt), 1636, 1211; 1H NMR (CDCl3, δ, ppm): 1.026-1.071 (t, 6 H), 2.325 (s, 6 H), 3.775-4.047 (m, 4 H), 5.335 (s, 1 H), 5.766 (s, 1 H), 7.282-7.473 (m, 4 H), 7.684-7.709 (d, 2 H, J = 7.5 Hz), 7.801 (s, 1 H), 8.254-8.344 (m, 3 H); mass: m/z 517.29 (M+ + 1, 100%)

Anal Calcd for C28H28N4O6: C 65.11, H 5.42, N 10.85; found: C 65.13, H 5.47, N 10.83

Synthesis of diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g)

General procedure: To a solution of appropriate 1,4-DHP (2, 10 mmol) in dichloromethane, was added HTIB (12 mmol) and the mixture was stirred at room temperature The progress of the reaction was moni-tored by TLC Reaction was completed in 4-5 min After the completion of reaction, the reaction mixture was washed with aqueous NaHCO3 solution Organic phase was then separated, dried and concentrated on water bath Crude product, thus obtained, was purified

by silica gel column chromatography using Pet ether/ EtOAc (20:1) as eluent to afford pure diethyl 2,6- dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g)

Characterization data of dimethyl 2,6-dimethyl-4-pyrazolylpyridine-3,5-dicarb oxylates (3a-g)

3a: M.p.: 111°C; yield: 68%; IR (νmax, cm-1, KBr): 1736, 1233; 1H NMR (CDCl3, δ, ppm): 0.911-0.997 (t, 6 H), 2.613 (s, 6 H), 3.910-4.07 (m, 4 H), 7.110-7.313 (m, 4 H), 7.817 (s, 1 H), 7.581-7.690 (m, 6 H); mass: m/z 470.20 (M++ 1, 100%)

Anal Calcd for C28H27N3O4: C 71.64, H 5.76, N 8.95; found: C 71.63, H 5.79, N 8.93

3b: M.p.: 105°C; yield: 69%; IR (νmax, cm-1, KBr): 1720, 1234; 1H NMR (CDCl3, δ, ppm): 0.913-0.960 (t, 6 H), 2.611 (s, 6 H), 2.468 (s, 3H), 3.923-4.072 (q, 4 H), 6.839-6.868 (d, 2H, J=8.7 Hz), 7.280-7.501 (m, 5 H), 7.732-7.759 (d, 2 H, J = 8.7 Hz), 7.905 (s, 1 H); mass: m/z 484.40 (M++ 1, 100%)

Anal Calcd for C29H29N3O4: C 72.05, H 6.00, N 8.70; found: C 72.06, H 6.05, N 8.70

3c: M.p.: 136°C; Yield- 72%; IR (νmax, cm-1, KBr): 1740, 1034; 1H NMR (CDCl3, δ, ppm): 0.913-0.998 (t, 6 H), 2.612 (s, 6 H), 3.808 (s, 3 H), 3.924-4.08 (q, 4 H), 6.835-6.864 (d, 2 H, J = 8.7 Hz), 7.311-7.501 (m, 5 H), 7.732-7.759 (d, 2 H, J = 8.7 Hz), 7.905 (s, 1 H); mass: m/z 500.29 (M++ 1, 100%)

Anal Calcd for C29H29N3O5: C 69.73, H 5.81, N 8.41; found: C 69.71, H 5.83, N 8.40

Trang 5

3d: M.p.: 121°C; yield: 70%; IR (νmax, cm-1, KBr): 1728,

1236, 1037;1H NMR (CDCl3, δ, ppm): 0.924-0.971 (t, 6

H), 2.615 (s, 6 H), 3.905-4.105 (q, 4 H), 6.987-7.044 (m,

2 H), 7.280-7.365 (m, 1 H), 7.469-7.622 (m, 4 H),

7.733-7.759 (d, 2 H, J = 7.8 Hz), 7.923 (s, 1 H); mass: m/z

488.36 (M++ 1, 100%)

Anal Calcd for C28H26N3O4F: C 68.99, H 5.38, N

8.62; found: C 68.95, H 5.37, N 8.63

3e: M.p.: 101-102°C, lit [20] M.p.: 101-102°C; Yield:

65%

3f: M.p.: 115°C; yield: 70%; IR (νmax, cm-1, KBr): 1734,

1030; 1H NMR (CDCl3, δ, ppm): 0.940-0.962 (t, 6 H),

2.617 (s, 6 H), 3.957-4.039 (q, 4 H), 7.200-7.495 (m, 7

H), 7.732-7.756 (d, 2 H, J = 7.2 Hz), 7.921 (s, 1 H);

mass: m/z 548.20, 550.20

Anal Calcd for C28H26N3O4Br: C 61.42, H 4.75, N

7.68; found: C 61.31, H 4.79, N 7.69

3g: M.p.: 172°C; yield: 68%; IR (νmax, cm-1, KBr): 1728,

1234, 1034;1H NMR (CDCl3, δ, ppm): 0.895-0.941 (t, 6

H), 2.632 (s, 6 H), 3.923-4.039 (m, 4 H), 7.279-7.410 (m,

3 H), 7.499-7.769 (m, 4 H), 7.960 (s, 1 H), 8.178-8.207

(d, 2 H, J = 7.5 Hz); mass: m/z 515.26 (M++ 1, 100%)

Anal Calcd for C28H26N4O6: C 64.37, H 4.98, N 10.73;

found: C 65.34, H 5.08, N 10.87

Pharmacology

Test microorganisms

Total six microbial strains were selected on the basis of

their clinical importance in causing diseases in humans

Two Gram-positive bacteria (S aureus MTCC 96 and B

subtilisMTCC 121); two Gram-negative bacteria (E coli

MTCC 1652 and P aeruginosa MTCC 741) and two

fungi (A niger and A flavus) the ear pathogens isolated

from the patients of Kurukshetra [21], were used in the

present study for the evaluation of antimicrobial

activ-ities of the chemical compounds All the cultures were

procured from Microbial Type Culture Collection

(MTCC), IMTECH, Chandigarh The bacteria and fungi

were subcultured on Nutrient agar and Sabouraud’s

dex-trose agar (SDA), respectively, and incubated aerobically

at 37°C

In vitro antibacterial activity

The antibacterial activities of compounds, 2a-g and

3a-g, were evaluated by the agar well diffusion method All

the cultures were adjusted to 0.5 McFarland standard,

which is visually comparable to a microbial suspension

of approximately 1.5 × 108 cfu/mL 20 mL of Mueller

Hinton agar medium was poured into each Petri plate,

and the agar plates were swabbed with 100 μL inocula

of each test bacterium and kept for 15 min for

adsorp-tion Using sterile cork borer of 8-mm diameter, wells

were bored into the seeded agar plates, and these were

then loaded with a 100μL volume with concentration of 2.0 mg/mL of each compound reconstituted in the dimethylsulphoxide (DMSO) All the plates were incu-bated at 37°C for 24 h Antibacterial activity of each compound was evaluated by measuring the zone of growth inhibition against the test organisms with zone reader (Hi Antibiotic zone scale) DMSO was used as a negative control whereas ciprofloxacin was used as a positive control This procedure was performed in three replicate plates for each organism [22,23]

Determination of minimum inhibitory concentration

Minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial compound that will inhibit the visible growth of a microorganism after over-night incubation MIC of the compounds against bacter-ial strains was tested through a macrodilution tube method as recommended by NCCLS [24] In this method, various test concentrations of chemically synthesized compounds were made from 256 to 1 μg/

mL in sterile tubes, 1-10 100 μL sterile Mueller Hinton Broth was poured in each sterile tube, and followed by addition of 200 μL test compound in tube 1 Twofold serial dilutions were carried out from tubes 1 to 10, and excess broth (100 μL) was discarded from the tube 10

To each tube, 100 μL of standard inoculum (1.5 × 108

cfu/mL) was added Ciprofloxacin was used as control Turbidity was observed after incubating the inoculated tubes at 37°C for 24 h

In vitro antifungal activity

The antifungal activity of the synthesized chemical com-pounds was evaluated by poison food technique The moulds were grown on SDA at 25°C for 7 days and used as inocula 15 mL of molten SDA (45°C) was poi-soned by the addition of 100 μL volume of each com-pound having concentration of 4.0 mg/mL, reconstituted in the DMSO, poured into a sterile Petri plate and allowed to solidify at room temperature The solidified poisoned agar plates were inoculated at the centre with fungal plugs (8-mm diameter), obtained from the actively growing colony and incubated at 25°C for 7 days DMSO was used as the negative control whereas fluconazole was used as the positive control The experiments were performed in triplicates Dia-meter of the fungal colonies was measured and expressed as percent mycelial inhibition determined by applying the following formula [25]:

Inhibition of mycelial growth % =(dc − dt) /dc × 100

where dc is the average diameter of fungal colony in negative control plates, and dt the average diameter of fungal colony in experimental plates

Trang 6

Additional material

Additional file 1: 1HNMR spectrum of compound 2b.

Additional file 2: 1HNMR spectrum of compound 2c.

Additional file 3: 1HNMR spectrum of compound 2e.

Additional file 4: 1HNMR spectrum of compound 2f.

Additional file 5: 1HNMR spectrum of compound 2g.

Additional file 6: 1HNMR spectrum of compound 3a.

Additional file 7: 1HNMR spectrum of compound 3b.

Additional file 8: 1HNMR spectrum of compound 3c.

Additional file 9: 1HNMR spectrum of compound 3d.

Additional file 10: 1HNMR spectrum of compound 3e.

Additional file 11: 1HNMR spectrum of compound 3f.

Additional file 12: 1HNMR spectrum of compound 3g.

Abbreviations

1,4-DHP: dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylates; DMSO:

dimethylsulphoxide; HTIB: hydroxy (tosyloxy)iodobenzene; MIC: minimum

inhibitory concentration; MTCC: microbial type culture collection; SDA:

Sabouraud dextrose agar.

Acknowledgements

We are thankful to the CSIR, New Delhi (Grant no CSIR 01 (2816)/07/EMR-II)

for providing financial assistance to accomplish this research The authors

are also grateful to the CSIR for the award of junior research fellowship to

Khalid Hussain.

Author details

1

Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136

119, India 2 Department of Chemistry, Guru Nanak Khalsa College,

Yamunanagar 135001, India 3 Department of Chemistry, Dyal Singh College,

Karnal 132 001, India4Department of Chemistry, Kurukshetra University,

Kurukshetra 136 119, India 5 Department of Microbiology, Kurukshetra

University, Kurukshetra 136 119, India

Competing interests

The authors declare that they have no competing interests.

Received: 21 March 2011 Accepted: 3 August 2011

Published: 3 August 2011

References

1 Loev B, Goodman M, Snader K, Tedeschi R, Macko E (1974) Hantzsch-type

dihydropyridine hypotensive agents J Med Chem 17:956 doi:10.1021/

jm00255a010.

2 Katzung BG (1998) Basic and clinical pharmacology Appleton & Lange,

Stamford

3 Bossert F, Meyer H, Wehinger E (1981) 4-Aryldihydropyridines, a new class

of highly active calcium antagonists Angew Chem Int Ed Engl 20:762.

doi:10.1002/anie.198107621.

4 Klusa V (1995) Cerebrocrast neuroprotectant cognition enhancer Drugs Fut

20:135

5 Godfraind T, Miller R, Wibo M (1986) Calcium antagonism and calcium entry

blockade Pharmacol Rev 38:321

6 Sausins A, Duburs G (1988) Synthesis of 1,4-dihydropyridines by

cyclocondensation reactions Heterocycles 27:269 doi:10.3987/REV-87-370.

7 Gaudio AC, Korolkovas A, Takahata Y (1994) Quantitative structure-activity

relationships for 1,4-dihydropyridine calcium channel antagonists (nifedipine

analogues): A quantum chemical/classical approach J Pharm Sci 83:1110.

doi:10.1002/jps.2600830809.

8 Cooper K, Fray M J, Parry M J, Richardson K, Steele J (1992)

1,4-Dihydropyridines as antagonists of platelet activating factor 1 Synthesis

and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives J

9 Yadav JS, Reddy VS, Reddy PT (2001) Unprecedented synthesis of hantzsch 1,4-dihydropyridines under biginelli reaction conditions Synth Commun 31:425 doi:10.1081/SCC-100000534.

10 Kumar R, Malik S, Chandra R (2009) Synthesis and antimicrobial evaluation

of (5-chloro-3-methyl-1-phenyl-1 H-pyrazol-yl)-dihydropyridines and 4-(5-chloro-3-methyl-1-phenyl-1 H-pyrazol-4-yl)-3,4-dihydropyrimidin-2-ones Ind J Chem 48B:718 –724

11 Böcker RH, Guengerich FP (1986) Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form

of cytochrome P-450 J Med Chem 29:1596 –1603 doi:10.1021/jm00159a007.

12 Prakash O, Singh SP (1994) Iodobenzene diacetate and related hypervalent iodine (III) reagents in the synthesis of heterocyclic compounds.

Aldrichimica Acta 27:15 –22

13 Prakash O, Sharma D, Kamal R, Kumar R, Nair RR (2009) The chemistry of α, β-chalcone ditosyloxy ketones: new and convenient route for the synthesis

of 1,4,5-trisubstituted pyrazoles from α, β-chalcone ditosylates Tetrahedron 68(49):10175 –10181

14 Prakash O, Kumar M, Kumar R (2010) A novel and convenient approach for tosyloxylation of aromatic ring of some ortho-substituted phenolic compounds using [hydroxy(tosyloxy)iodo]benzene Tetrahedron 66(31):5827 –5832 doi:10.1016/j.tet.2010.05.042.

15 Varvoglis A (1997) Chemical transformations induced by hypervalent iodine reagents Tetrahedron 53:1179 doi:10.1016/S0040-4020(96)00970-2.

16 Ladziata U, Zhdankin VV (2006) Hypervalent (V) reagents in organic synthesis Arkivoc ix:26 –58

17 Zhdankin VV (2009) Hypervalent (III) reagents in organic synthesis Arkivoc i:1 –62

18 Lee K-H, Ko K-Y (2002) Aromatization of Hantzsch 1,4-dihydropyridines using [Hydroxy(tosyloxy)iodo]benzene Bull Korean Chem Soc 23(11):1505 –1506

19 Kira MA, Abdel-Rahman MO, Gadalla KZ (1969) Vilsmeier reaction-III cyclization of hydrazones to pyrazoles Tetrahedron Lett 10:109 –110 doi:10.1016/S0040-4039(01)88217-4.

20 Murugan R, Ramamoorthy K, Sundarrajan S, Ramakrishna S (2011) Simple and efficient synthesis of 2,6-dialkyl-3,5-dialkoxycarbonyl-4-(3-aryl-1-phenyl-pyrazol-4-yl) using TPAP/NMO as a catalyst under mild conditions Tetrahedron

21 Aneja KR, Sharma C, Joshi R (2010) Fungal infection of the ear: a common problem in the north eastern part of Haryana Int J Pediatr Otorhinolaryngol 74:604 –607 doi:10.1016/j.ijporl.2010.03.001.

22 Ahmad I, Beg AJ (2001) Antimicrobial and phytochemical studies on 45 Indian medicinal plants against multi-drug resistant human pathogens J Ethnopharmacol 74:113 –123 doi:10.1016/S0378-8741(00)00335-4.

23 Andrews JM (2001) Determination of minimum inhibitory concentrations J Antimicrob Chemother 48:5 –16

24 NCCLS (2000) Method for dilution antimicrobial susceptibility test for bacteria that grow aerobically approved standards National Committee for Clinical Standards, Villanova, PA, 5

25 Al-Burtamani SKS, Fatope MO, Marwah RG, Onifade AK, Al-Saidi SH (2005) Chemical composition, antibacterial and antifungal activities of the essential oil of Haplophyllum tuberculatum J Ethnopharmocol 96:107 –112.

doi:10.1016/j.jep.2004.08.039.

doi:10.1186/2191-2858-1-5 Cite this article as: Prakash et al.: Synthesis and antimicrobial evaluation

of new 1,4-dihydro-4-pyrazolylpyridines and 4-pyrazolylpyridines Organic and Medicinal Chemistry Letters 2011 1:5.

Ngày đăng: 21/06/2014, 06:20

TỪ KHÓA LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm